Mesothelin-Expressing TumorsPhase 1NCT06623396Papers
M28z1XXPD1DNR CAR
Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
9 Phase 1 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Breast9 studies
Mesothelin-Expressing TumorsPhase 1NCT06623396Papers
Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
HR+/HER2- Breast Cancer Brain MetastasesPhase 1/2NCT04923542
SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
Metastatic HER2-Negative Breast CancerPhase 1NCT05029999
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
PTEN-Altered Advanced Solid Tumors and HER2-Negative Breast CancerPhase 1NCT04997993
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
HR-Positive, HER2-Low or Ultralow Metastatic Breast CancerPhase 1/2NCT07198724
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Triple Negative Breast CancerPhase 1NCT05504707Papers
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
Triple-Negative Breast CancerPhase 1NCT06324240
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Advanced ER-Positive HER2-Negative Breast CancerPhase 1NCT05900895
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
Metastatic Hormone Receptor-Positive Breast CancerPhase 1NCT07137871
Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy